Lung cancer is the leading cause of death from cancer worldwide with limited available treatment options
in absence of specific molecular alteration. New therapeutic approaches for addressing non small cell lung
cancer (NSCLC) are urgently needed. Angiogenesis plays a central role in the tumor growth and metastatic dissemination
which stimulates multiple cells to build new abnormal microvessels and leads to tumor microenvironment
alterations. This process involves many factors, such as, the vascular endothelial growth factor (VEGF) that
has a dominant role, the fibroblast growth factors (FGFs) and the plateled-derived growth factor (PDGF) that together
contribute to resistance to VEGF/VEGFR- directed therapy. To date, bevacizumab is currently the only angiogenesis
inhibitor that has been approved for the treatment of patients with advanced NSCLC in first-line setting.
Moreover, in the last year, two new antiangiogenic agents have been approved for the treatment of patients with
advanced NSCLC in second line setting. This review describes the new antiangiogenic agents in the treatment of advanced NSCLC.
Keywords: Angiogenesis, bevacizumab, multi-target inhibitors, non-small cell lung cancer, targeted therapy, VEGF.
Rights & PermissionsPrintExport